长春瑞滨联合卡铂治疗晚期非小细胞肺癌的临床研究

Clinical research of vinorelbine combined with carboplatin in the treatment of advanced non-small cell lung cancer patients

目的:观察国产长春瑞滨联合卡铂治疗晚期非小细胞肺癌的临床疗效和毒副反应。方法:45例非小细胞肺癌患者均经细胞学或组织学证实,所有患者均进行长春瑞滨联合卡铂方案化疗,其中长春瑞滨25mg/m2,静脉注射,第1、5天;卡铂300mg/m2,静脉滴注,第1天,21天为1周期。结果:45例患者中,CR2例,PR21例,SD13例,PD9例,总有效率为51.1%。其中初治患者25例,CR+PR14例,有效率56.0%;复治20例,CR+PR6例,有效率30.0%。毒性反应主要为胃肠道反应和骨髓抑制,其次为局部红肿和疼痛等静脉炎表现。结论:长春瑞滨联合卡铂方案是治疗晚期非小细胞肺癌较为理想的方案之一。

Objective：To investigate the clinical efficacy and side effects of domestic vinorelbine with carboplatin in advanced non-small cell lung cancer （ NSCLC ） patients. Methods ： All 45 cases with NSCLC were identified by cytological or histological methods and treated with vinorelbine （25mg/m^2 iv d1 ,d5 ） and carboplatin （ 300mg/m^2 iv d1 ） for 3 weeks as a cycle. Results：Two cases of complete remission （CR）, 21 cases of partial remission （PR）, 13 cases of stable disease（SD） and 9 cases of progressive disease （PD） were achieved in all of the 45 cases. The response rate （ CR ＋ PR） was 56.0% of the previously untreated 25 patients and 30% previously treated group respectively with overall response rate was 51.1%. Significant difference was observed between the two groups （ P 〈 0. 05 ）. The main side effects were digestive tract reaction and myelosuppression. Vein phlebitis such as local skin red and pain was mild in this protocol. Condusion：Vinorelbine combined with carboplatin maybe one of the best regimens in the treatment of patients with advanced NSCLC.